Metabolic consequences of oncogenic IDH mutations

Area of Science:

• Biochemistry
• Oncology
• Metabolic pathways

Background:

• Specific point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are prevalent in cancers like AML, low-grade gliomas, and chondrosarcomas.
• These mutations lead to the production of d-2-hydroxyglutarate (d-2HG), a metabolite that accumulates in tumors and disrupts normal cellular functions.

Purpose of the Study:

• To review the impact of IDH1 and IDH2 mutations on cellular metabolism, epigenetics, and other biochemical functions.
• To discuss these metabolic alterations in the context of current therapeutic strategies targeting IDH-mutated cancers.

Main Methods:

• Literature review of studies investigating IDH1/IDH2 mutations and their consequences.
• Analysis of the role of d-2HG in cancer development and progression.
• Examination of ongoing clinical trials for IDH inhibitors.

Main Results:

• IDH1/IDH2 mutations inactivate wild-type enzyme activity and confer neomorphic function, producing d-2HG.
• Accumulated d-2HG affects α-ketoglutarate-dependent dioxygenase activity, impacting cellular functions and epigenetics.
• IDH1/IDH2 are key enzymes in the tricarboxylic acid (TCA) cycle, and their mutations significantly alter intermediary metabolism.

Conclusions:

• Oncogenic IDH mutations result in the loss of wild-type metabolic activity, presenting a therapeutically exploitable vulnerability.
• Targeting the neomorphic activity of mutant IDH1 and IDH2 is a key focus of ongoing Phase I/II clinical trials for various solid and blood tumors.
• Continued investigation into the metabolic consequences of IDH mutations is crucial for developing effective cancer therapies.